CDH13 and chronic myelogenous leukemia, BCR-ABL1 positive: This study investigated the effects of saRNA-based CDH13 activation on BCR-ABL1-independent imatinib resistance in CML and its underlying mechanism, and proposes a unique treatment method to overcome imatinib resistance.